Shares of AnaptysBio Inc. (ANAB) are down over 50% from their 52-week high of $41.31, recorded last August, with the stock now hovering around the $20 level.
This clinical-stage biotechnology company is developing immunology therapeutics for autoimmune and inflammatory diseases. Its lead drug candidate is Rosnilimab, which is in a phase IIb trial for the treatment of rheumatoid arthritis and in a phase II trial for the treatment of ulcerative colitis.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com